The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Immune checkpoint inhibitor treatment in PD-L1-negative gastroesophageal cancer tumors.
 
Mohamed E. Salem
Consulting or Advisory Role - Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Exelixis; Exelixis; Merck; Novartis; Pfizer; QED Therapeutics; Taiho Pharmaceutical
Speakers' Bureau - BMS; Daiichi Sankyo/Astra Zeneca; Merck; Pfizer; Taiho Pharmaceutical
 
Sharon Wu
Employment - Caris Life Sciences
Research Funding - Caris Life Sciences
 
Joanne Xiu
No Relationships to Disclose
 
Sachin Kumar Deshmukh
Employment - Caris Life Sciences
 
David Foureau
No Relationships to Disclose
 
Jimmy J. Hwang
Consulting or Advisory Role - AstraZeneca; Caris Centers of Excellence; Ipsen
Research Funding - Boehringer Ingelheim (Inst); Caris Centers of Excellence (Inst)
 
John Marshall
Employment - Caris Life Sciences; Indivumed
Leadership - 2curex
Honoraria - AstraZeneca/MedImmune; Bayer/Onyx; Caris Life Sciences; Daiichi Sankyo/Lilly; Merck; Pfizer; Seagan; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Caris Life Sciences; Genentech/Roche; Merck; Pfizer; Seagen; Taiho Pharmaceutical
Speakers' Bureau - Caris Life Sciences; Merck; Pfizer; Seagan; Taiho Pharmaceutical
Research Funding - Genentech; Natera
 
Richard M. Goldberg
Stock and Other Ownership Interests - Advanced Chemotherapy Technologies; Compass Therapeutics; Quest Diagnostics
Consulting or Advisory Role - Abbvie; Adaptimmune; AstraZeneca; Bayer; Compass Therapeutics; Eisai/H3 Biomedicine; G1 Therapeutics; GeneCentric; GlaxoSmithKline; IQvia; Merck; RIN Institute; Sorrento Therapeutics; Taiho Pharmaceutical; Takeda; UpToDate; Valar Labs
Expert Testimony - Taiho Pharmaceutical
 
Heinz-Josef Lenz
Honoraria - Bayer; Boehringer Ingelheim; Fulgent Genetics; G1 THerapeutics; Isofol Medical; Jazz Pharmaceuticals; Merck Serono; Oncocyte; Roche
Consulting or Advisory Role - 3T BioSciences; Bayer; BMS; Fulgent Genetics; GlaxoSmithKline; Merck Serono; Roche
Travel, Accommodations, Expenses - Bayer; BMS; Merck Serono
 
Thanachai Sanlung
Honoraria - Ipsen; Takeda
Research Funding - AstraZeneca; GlaxoSmithKline
 
Rachna T. Shroff
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Genentech; Jazz Pharmaceuticals; Merck; Merus
Research Funding - Actuate Therapeutics; Bristol-Myers Squibb; Exelixis; Faeth Therapeutics; Fujifilm; Immunovaccine; Lisata; Loxo/Lilly; Merck; NGM Biopharmaceuticals; Novocure; Nucana; Rafael Pharmaceuticals; Seagen
 
Wei Zhang
No Relationships to Disclose
 
Matthew James Oberley
Employment - Caris Life Sciences
Leadership - Caris Life Sciences
Stock and Other Ownership Interests - Caris Life Sciences
Travel, Accommodations, Expenses - Caris Life Sciences
 
Benjamin Adam Weinberg
Employment - Apple (I)
Stock and Other Ownership Interests - Apple (I)
Honoraria - Primum
Consulting or Advisory Role - AstraZeneca/Daiichi Sankyo; Bayer; DoMore Diagnostics; Foundation Medicine; Merus NV
Speakers' Bureau - Bayer; Daiichi Sankyo/Astra Zeneca; Merus NV; Natera; Seagen; Sirtex Medical; Taiho Pharmaceutical
Research Funding - Abbvie (Inst); BioXCel therapeutics (Inst); Immune System Key (Inst); Ipsen (Inst); Merck (Inst)
Expert Testimony - AstraZeneca
Travel, Accommodations, Expenses - Merus NV
 
Sanjay Goel
Stock and Other Ownership Interests - Johnson and Johnson; Merck; Moderna Therapeutics
Honoraria - GlaxoSmithKline
Research Funding - Amgen (Inst); BioMed Valley Discoveries (Inst); Deciphera (Inst); Dragonfly Therapeutics (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); Takeda (Inst); Xilio Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - I have a patent with a co-inventor, John Mariadason, Ph.D, entitled "Method Of Determining The Sensitivity Of Cancer Cells To EGFR Inhibitors Including Cetuximab, Panitumumab And Erlotinib.", Patent No. 20090258364